Sign in
TerminatedNo phase

Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

Key facts

Who runs it
OHSU Knight Cancer Institute
Where
Portland, United StatesSee the site
Trial code
Status
Terminated
People taking part
9 people enrolled
Started
7 Feb 2019
Ended
11 Jan 2024
Type of study
Interventional
Treatments tested
  • Quality-of-Life Assessment
  • Questionnaire Administration
  • Stereotactic Body Radiation Therapy
Record updated
7 March 2025
Why it stopped
PI decision

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Ability to understand and the willingness to sign a written informed consent document
  • Must be listed or recommended to be listed for orthotopic liver transplantation at the participating institution
  • Have a Child-Pugh (CP) score >= B8
  • Eastern Clinical Oncology Group (ECOG) performance status =< 2, or Karnofsky performance scale > 60
  • Must have a life expectancy > 12 weeks
  • Safe radiation treatment planning parameters that adhere to all organs at risk constraints per section 5.1 of the protocol. If normal organs at risk constraints (including at least 700cc of uninvolved liver) are unable to be met at the lowest dose modification (30 Gy in 5 fractions), the patient is deemed ineligible for SBRT and deemed a screen failure
  • Except for prior radiotherapy or radioembolization, other prior therapies to previously treated lesions, are permitted
  • People of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of SBRT. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year without an alternative medical cause; Note: Abstinence is acceptable if this is the preferred contraception for the participant
  • No other prior invasive malignancy is allowed except for the following: adequately treated basal (or squamous cell) skin cancer, in situ breast or cervical cancer. Stage I or II invasive cancer treated with a curative intent without evidence of disease recurrence for at least five years

Who cannot take part

  • Prior radiotherapy to the upper abdomen or radioembolization of the liver, or prior thermal ablation to the target lesion
  • Participation in another concurrent treatment protocol
  • For fiducial marker placement:; Have a gold allergy; Any coagulopathy preventing safe fiducial placement
  • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written informed consent
  • Participants have any one of the following liver tumor characteristics:; Have > 5 liver tumors, or; Maximal diameter > 5 cm
  • Complete obstruction of portal venous flow to the segment of liver that includes the target lesion
  • Contraindication to both contrast enhanced magnetic resonance imaging (MRI) and contrast enhanced computed tomography (CT) (i.e. unable to undergo follow-up imaging or SBRT treatment planning)
  • Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment

Where in United States

  • OHSU Knight Cancer InstitutePortland, United States

About the trial

What the trial wants to find out

This trial studies how well stereotactic body radiation therapy works in treating patients with liver cancer. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.

The group in the trial

  • Treatment (SBRT)Treatment being tested

    Patients undergo SBRT on days 1, 3, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity.

    Treatment: Quality-of-Life Assessment, Questionnaire Administration, and Stereotactic Body Radiation Therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Study to Assess Feasibility of Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients Awaiting Liver Transplantation
Record updated
7 March 2025